Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lab values in neonates with hypoxic ischemic encephalopathy over time during and after therapeutic hypothermia.

Frontiers in pediatrics·2026
Same author

Nutrition in infants with hypoxic-ischemic encephalopathy: insights from a single-center experience on parenteral and enteral feeding during therapeutic hypothermia.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2025
Same author

Idiopathic Inflammatory Myopathies.

Continuum (Minneapolis, Minn.)·2025
Same author

Digital biomarkers as predictors of brain injury in neonatal encephalopathy.

Frontiers in pediatrics·2025
Same author

Item selection for the development and validation of a revised classification criteria for adult and juvenile idiopathic inflammatory myopathies: MyoROC project.

Seminars in arthritis and rheumatism·2025
Same author

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.

Therapeutic advances in neurological disorders·2025
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Inflammatory myopathies.

B Jane Distad1, Anthony A Amato, Michael D Weiss

  • 1Department of Neurology, Neuromuscular Division, University of Washington, School of Medicine, Seattle, WA, 98195, USA, jdistad@uw.edu.

Current Treatment Options in Neurology
|January 12, 2011
PubMed
Summary
This summary is machine-generated.

Current treatments for idiopathic inflammatory myopathies focus on immune suppression, primarily for polymyositis (PM) and dermatomyositis (DM). However, evidence supporting these therapies is limited, especially for inclusion body myositis (IBM).

Related Experiment Videos

Last Updated: Jun 5, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Area of Science:

  • Rheumatology and Immunology
  • Neurology
  • Dermatology

Background:

  • Idiopathic inflammatory myopathies (IIMs) are chronic autoimmune diseases primarily treated with immunosuppressive therapies.
  • Current treatments are mainly directed at polymyositis (PM) and dermatomyositis (DM), with limited options for inclusion body myositis (IBM).
  • Evidence from randomized controlled trials supporting existing therapies for PM and DM is scarce.

Purpose of the Study:

  • To review the current therapeutic landscape for idiopathic inflammatory myopathies.
  • To highlight the efficacy and limitations of existing treatments, including corticosteroids and immunosuppressive drugs.
  • To discuss emerging immunotherapies and their potential in managing IIMs.

Main Methods:

  • Review of existing literature on the treatment of idiopathic inflammatory myopathies.
  • Analysis of the role of corticosteroids, steroid-sparing immunosuppressive agents, and newer immunotherapies.
  • Examination of treatment efficacy and side effect profiles for different IIM subtypes.

Main Results:

  • Oral corticosteroids remain the first-line treatment for PM and DM despite limited supporting evidence.
  • Steroid-sparing agents like azathioprine and methotrexate are used as second-line therapies, requiring careful monitoring for side effects.
  • Intravenous immunoglobulin and rituximab show promise, particularly for DM, but cost and efficacy in IBM remain challenges.

Conclusions:

  • The treatment of idiopathic inflammatory myopathies relies heavily on immune suppression, with varying degrees of evidence.
  • Effective treatments for inclusion body myositis (IBM) are still lacking.
  • Further research into novel immunotherapies is crucial for improving outcomes in all forms of IIMs.